Trial | NCT01000896  Report issue

Title

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    27
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
Study Started
Jan 31
2010
Primary Completion
Sep 30
2010
Anticipated
Study Completion
Mar 31
2011
Anticipated
Last Update
Feb 04
2010
Estimate

Drug AZD0530

film coated tablet, PO, daily

Drug Carboplatin

intravenous, 3 weeks

  • Other names: Paraplatin

Drug paclitaxel

intravenous, 3 weeks

  • Other names: Taxol

AZD0530 + carboplatin and paclitaxel Experimental

AZD0530 in combination with carboplatin and paclitaxel

Criteria 

Inclusion Criteria:

Japanese patients with non small cell lung cancer or epithelial ovarian cancer
Must be suitable for treatment with carboplatin and paclitaxel
Relatively good overall health other than cancer

Exclusion Criteria:

Poor bone marrow function (not producing enough blood cells).
Poor liver or kidney function.
Patients unable to discontinue drugs known to be potent inhibitors or inducers of CYP3A4 within 2 weeks prior to registration
No Results Posted